- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03723785
A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems
March 5, 2021 updated by: Novo Nordisk A/S
Investigation of Pharmacokinetics and Safety Profile of a Single Dose NNC0148-0287 C (Insulin 287) in Subjects With Various Degrees of Renal Impairment
This study will be conducted to look at the effect of decreased kidney function when getting one dose of insulin 287 and to guide dosing recommendations in people who have altered kidney function.
Insulin 287 works in the body for a long time (long-acting).
It is taken once a day by injecting under the skin.
The main target patient group for insulin 287 is people with type 2 diabetes.
Participants will get just one injection.
The study will last for up to 80 days.
Participants will have 11 out-patient visits with the study doctor and one in-house visit of 3 days and 2 nights.
Participants will have some assessments like several blood draws, electrocardiograms (ECGs), urine collections and capillary blood sugar tests.
Participants cannot take part if they are hypersensitive to the study medicine, if they received any investigational product within 90 days before screening, or if they have certain diseases e.g.
HIV or hepatitis or heart problems.
Participants have to take photos if they experience any allergic reactions and send them to their study doctor.
Participants' kidney function will be examined by a so called "Iohexol test".
Study Overview
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
- Body mass index between 18.5 and 32.0 kg/sqm (both inclusive).
- Meeting the pre-defined Glomerular Filtration Rate (GFR) values based on a measured GFR using an exogenous substance as tracer (renal group 1-4) or being in treatment with haemodialysis (renal group 5).
Exclusion Criteria:
- Known or suspected hypersensitivity to trial product or related products.
- Impaired liver function defined as Alanine Aminotransferase (ALT) greater than or equal to 2.5 times or Bilirubin greater than 1.5 times upper limit of normal at screening.
- Drugs known to affect creatinine clearance including cephalosporin and aminoglycoside antibiotics, flucytosine, cisplatin, cimetidine and trimethoprim within 14 days or 5 half-lives prior to the day of dosing of IMP.
- Renal group 1 (healthy subjects) exclusively: Unwilling to avoid use of prescription medicinal products or non-prescription drugs, except routine use of vitamins, occasional use of paracetamol, topical medication and contraceptives, within 14 days prior to the day of dosing.
- Renal Group 2-5 (renal impairment) exclusively: 1) Any disorder, except for conditions associated with renal impairment in the groups of subjects with reduced renal function, which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol. Subjects with heart failure of functional class III-IV according to New York Heart Association (NYHA), subjects with Chronic obstructive pulmonary disease (COPD) grade 4 according to Global Initiative on Obstructive Lung Disease (GOLD), subjects with asthma step 5 according to Global Initiative for Asthma (GINA), subjects diagnosed with diabetes, subjects with uncontrolled treated/untreated hypertension (systolic blood pressure greater than or equal to 180 mmHg and /or diastolic blood pressure greater than or equal to 100 mmHg assessed in supine position) and other co-morbidities in terminal stages or which are decompensated or unstable should not be included in the study. 2) Subject requiring haemodialysis treatment unable or unwilling to undergo haemodialysis scheduled according to the standard clinical regimen throughout the trial period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with normal renal function
Participants with normal renal function (glomerular filtration rate [GFR] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
|
Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
Other Names:
|
Experimental: Participants with mildly decreased renal function
Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
|
Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
Other Names:
|
Experimental: Participants with moderately decreased renal function
Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
|
Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
Other Names:
|
Experimental: Participants with severely decreased renal function
Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
|
Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
Other Names:
|
Experimental: Participants with end-stage renal disease
Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
|
Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single dose
Time Frame: From 0 to 840 hours after trial product administration (visit 2 (study day 1))
|
Measured in pmol*h/L
|
From 0 to 840 hours after trial product administration (visit 2 (study day 1))
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax,I287,SD: Maximum observed serum insulin 287 concentration after a single dose
Time Frame: From 0 to tz hours after trial product administration (visit 2 (study day 1)), where tz is the time of the last quantifiable concentration
|
Measured in pmol/L
|
From 0 to tz hours after trial product administration (visit 2 (study day 1)), where tz is the time of the last quantifiable concentration
|
tmax,I287,SD: Time to maximum observed serum insulin 287 concentration after a single dose
Time Frame: From 0 to tz hours after trial product administration (visit 2 (study day 1)).
|
Measured in hours
|
From 0 to tz hours after trial product administration (visit 2 (study day 1)).
|
Number of adverse events
Time Frame: From trial product administration (visit 2 (study day 1)) until visit 13 (study day 43)
|
Number of events
|
From trial product administration (visit 2 (study day 1)) until visit 13 (study day 43)
|
Change in anti-insulin 287 antibody level
Time Frame: From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)
|
Measured in % B/T (percentage of bound tracer measured after precipitation to total tracer)
|
From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)
|
Change in anti-insulin 287 antibody titres
Time Frame: From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)
|
Number of dilutions
|
From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)
|
Positive cross-reactive anti-human insulin antibodies
Time Frame: At visit 13 (study day 43)
|
Number of patients with/without positive cross-reactive anti-human insulin antibodies
|
At visit 13 (study day 43)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2018
Primary Completion (Actual)
September 6, 2019
Study Completion (Actual)
September 6, 2019
Study Registration Dates
First Submitted
October 26, 2018
First Submitted That Met QC Criteria
October 26, 2018
First Posted (Actual)
October 30, 2018
Study Record Updates
Last Update Posted (Actual)
March 8, 2021
Last Update Submitted That Met QC Criteria
March 5, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1436-4226
- 2017-004529-34 (EudraCT Number)
- U1111-1204-8972 (Other Identifier: World Health Organization)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Insulin icodec
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Mexico, Puerto Rico, Canada, Denmark, France, Austria, Taiwan, Czechia, Brazil, China, Argentina
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Poland, United States, Japan, Korea, Republic of, Germany, Bulgaria, South Africa, Portugal, Ukraine
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Austria
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 1United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey
-
Novo Nordisk A/SRecruitingDiabetes Mellitus, Type 2Austria
-
Novo Nordisk A/SActive, not recruitingDiabetes Mellitus, Type 2Finland, Taiwan, United States, Korea, Republic of, China, Australia, Portugal, Japan, India, Russian Federation, Norway, Italy, Mexico, Turkey, Poland, Belgium, Bulgaria, Croatia, Puerto Rico, Romania, Serbia, South Africa
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes | Type 2 Diabetes MellitusGermany